2018 was a record year for biopharma initial public offerings (IPOs), with an all-time high of $6.3 billion raised by 58 U.S. companies as of December 17, according to Renaissance Capital, compared with 36 companies garnering some $4 billion in 2017.
But with the broader stock market reeling in recent weeks from investor jitters over U.S. trade policy and the direction of China’s economy, it remains to be seen whether 2019’s IPO market will be as red-hot as this past year’s proved to be.
